ClinicalTrials.gg
RecruitingNCT07860645Updated Oct 16, 2026

Effect of Lifestyle Intervention on Menopausal Symptoms, Sleep Quality, and Anxiety in Peri- and Postmenopausal Women

An interventional study of Structured Lifestyle Education and Standard Care (in control arm) in Perimenopause, Postmenopause and Menopause, sponsored by Konya Beyhekim Training and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 40 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Konya Beyhekim Training and Research Hospital · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 16, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
40 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 393 studies in Sleep Initiation and Maintenance Disorders with a site in Turkey — 98 open to participants now, 111 under way, none of them phase 3. Sleep Initiation and Maintenance Disorders · Turkey.

Planned enrollment
48th of 311
100 · median 60
Started
2026
with 67 others
No phase
309 of 393
75 open now
Primary completion
2027-05
later than 102 of 110 live
Registered
378th of 393
by date

Among the 393 studies in Sleep Initiation and Maintenance Disorders with a site in Turkey, this one is the 48th largest by planned enrollment of the 311 interventional ones that give a count, is one of 68 that started in 2026, is one of 309 with no phase, reaches primary completion later than 102 of the 110 other live ones, and was the 378th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

98 of the 393 studies in Sleep Initiation and Maintenance Disorders with a site in Turkey are open now. Recruiting first, the newest first:

92 more — sign in →

All 98 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 40 Years to 55 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 393 studies in Sleep Initiation and Maintenance Disorders with a site in Turkey, or all of them as a file.
02

Study summary

Menopause is a biological process characterized by the permanent cessation of menstruation, often accompanied by vasomotor symptoms, sleep disturbances, anxiety, and impaired quality of life. In primary healthcare settings, structured lifestyle interventions offer low-cost, safe, and sustainable non-pharmacological management strategies.

The objective of this prospective, randomized controlled trial is to evaluate whether a structured lifestyle educational intervention leads to significant improvements in menopausal symptom severity, sleep quality, and anxiety levels compared with a control group receiving routine clinical care among perimenopausal and postmenopausal women aged 40 to 55 years. Primary and secondary outcomes are evaluated using the Menopause Rating Scale (MRS), Pittsburgh Sleep Quality Index (PSQI), and Generalized Anxiety Disorder-7 (GAD-7) at baseline and at 24 weeks.

Read the detailed description

Background and Objective:

In perimenopausal and postmenopausal women aged 40-55 presenting to primary care, this study evaluates the impact of a structured lifestyle modification program on menopausal symptoms, sleep quality, and anxiety compared with a control group.

Methods and Design:

This prospective, parallel-group, randomized controlled trial is conducted at Selcuklu Ardicli Educational Family Health Center (Units 218, 225, 239, 240) affiliated with Konya Beyhekim Training and Research Hospital.

Eligible women aged 40-55 years with baseline MRS scores between 9 and 31 will be randomized in a 1:1 allocation ratio using a computer-generated block randomization list (block size of 4) via sequentially numbered, opaque, sealed envelopes:

Intervention Group: Receives face-to-face structured educational counseling covering physical activity recommendations, dietary guidance, sleep hygiene, and stress reduction principles at baseline. Re-evaluation is performed face-to-face at 24 weeks.

Control Group: Receives standard clinical care without structured lifestyle education. At the end of the 24-week follow-up and completion of final questionnaires, the same lifestyle education is provided to ensure equal contribution to both groups.

Outcome Assessments:

Questionnaires administered at baseline and Week 24:

Menopause Rating Scale (MRS) for somatic, psychological, and urogenital symptoms.

Pittsburgh Sleep Quality Index (PSQI) for subjective sleep quality over the previous month.

Generalized Anxiety Disorder-7 (GAD-7) for anxiety symptoms over the past two weeks.

In addition, national electronic health records (e-Nabız) will be reviewed at Month 6 for new antidepressant initiation, systemic hormone replacement therapy initiation, prescription counts of non-steroidal anti-inflammatory drugs (NSAIDs), and emergency department visits.

Sample Size Calculation:

Calculated using G*Power 3.1.9.4 with repeated measures ANOVA (within-between interaction; effect size f=0.20, alpha=0.05, power=0.95, 2 groups, 2 measurements, correlation=0.50), yielding a minimum of 84 participants. Accounting for a 10% dropout rate, a total of 100 participants (50 intervention group, 50 control group) will be enrolled.

03

Conditions studied

  • Perimenopause
  • Postmenopause
  • Menopause

Keywords

  • Menopausal Symptoms
  • Lifestyle Intervention
  • Sleep Quality
  • Anxiety
  • Primary Health Care
  • Randomized Controlled Trial
04

Who can participate

Ages eligible
40 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Female patients aged 40 to 55 years presenting to the Educational Family Health Center

Categorized into one of the defined reproductive stages: late perimenopause, early (0-5 years), or late postmenopause (>5 years)

Reporting complaints in at least one key menopausal domain: hot flashes/night sweats, sleep problems, or mood changes (anxiety, irritability, depressive mood)

Baseline Menopause Rating Scale (MRS) total score between 9 and 31 (inclusive)

Literate and capable of comprehending and completing study questionnaires

Accessible for the 24-week follow-up evaluation

History of compensated chronic disease (e.g., controlled diabetes mellitus, hypertension, atherosclerotic cardiovascular disease, hyperlipidemia)

Provision of written

Exclusion criteria

Exclusion Criteria:

Age younger than 40 or older than 55 years

History of hysterectomy or bilateral oophorectomy

Severe cognitive impairment or inability to complete questionnaires

Inability or refusal to provide written

Previously diagnosed severe psychiatric illness (e.g., psychotic disorders, bipolar disorder)

Baseline Menopause Rating Scale (MRS) total score \<9 or ≥32

History of decompensated chronic disease (e.g., uncontrolled hypertension, unstable cardiovascular disease, decompensated diabetes mellitus)

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Lifestyle Intervention Group (Education First)

    Participants receive structured education on healthy lifestyle modifications during the menopausal transition, focusing on regular physical activity, dietary guidance, sleep hygiene, and stress reduction principles at baseline. Re-evaluation is performed face-to-face at 24 weeks.

    Behavioral: Structured Lifestyle Education

  • Active comparator
    Control Group (Wait-list Control)

    Participants receive standard clinical care without structured lifestyle education during the 24-week study period. Follow-up questionnaires are completed at 24 weeks, after which the healthy living educational information is provided.

    Other: Standard Care (in control arm)

Interventions

  • BehavioralStructured Lifestyle Education

    Face-to-face structured educational counseling covering regular physical activity recommendations, dietary guidance, sleep hygiene principles, and stress management strategies tailored for perimenopausal and postmenopausal women.

  • OtherStandard Care (in control arm)

    Participants continue with standard routine care and health follow-up without the structured menopause lifestyle education during the first 6 months.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Menopause Rating Scale (MRS) Total Score at 24 Weeks

    Assessed using the Menopause Rating Scale (MRS), which evaluates somatic, psychological, and urogenital symptoms across 11 items. Each item is scored on a 5-point Likert scale (0=none to 4=very severe), yielding a total score ranging from 0 to 44. Higher scores reflect greater symptom severity. Change is defined as the score at 24 weeks minus the baseline score.

    Time frame: Baseline and 24 weeks

Secondary outcomes

  1. Change from Baseline in Pittsburgh Sleep Quality Index (PSQI) Score at 24 Weeks

    Subjective sleep quality over the previous month assessed using the Pittsburgh Sleep Quality Index (PSQI). The global score ranges from 0 to 21, where scores greater than 5 indicate poor sleep quality. Higher scores reflect worse sleep quality. Change is calculated as the score at 24 weeks minus the baseline score.

    Time frame: Baseline and 24 weeks

  2. Change from Baseline in Generalized Anxiety Disorder-7 (GAD-7) Score at 24 Weeks

    Anxiety symptoms over the previous two weeks assessed using the Generalized Anxiety Disorder-7 (GAD-7) scale. The total score ranges from 0 to 21, categorized as minimal (0-4), mild (5-9), moderate (10-14), and severe (15-21) anxiety. Higher scores indicate greater anxiety symptom severity. Change is defined as the score at 24 weeks minus the baseline score.

    Time frame: Baseline and 24 weeks

  3. Rate of New Medication Initiation (Antidepressants or HRT) at 24 Weeks

    Percentage of participants who were prescribed a new antidepressant or systemic hormone replacement therapy (HRT) during the 24-week follow-up period, assessed via electronic health records (e-Nabiz system).

    Time frame: From baseline up to 24 weeks

  4. Number of Emergency Department Visits at 24 Weeks

    Total number of all-cause and symptom-related emergency department admissions per participant during the 24-week study period, extracted from electronic health records (e-Nabiz system).

    Time frame: From baseline up to 24 weeks

  5. Total Count of NSAID Prescriptions at 24 Weeks

    Total number of non-steroidal anti-inflammatory drug (NSAID) prescriptions filled per participant over the 24-week follow-up period, assessed via electronic health records (e-Nabiz system)

    Time frame: From baseline up to 24 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data collected during the study will not be shared publicly to protect participant privacy and confidentiality.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for May 2027, 7 months after the start.

Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 7 months is below that.

Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 6, 2026
StartActual
Oct 15, 2026
Primary completionEst.
May 15, 2027
CompletionEst.
Jul 31, 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
Konya Beyhekim Training and Research Hospital is now Recruiting
Oct 16, 2026
Registered
First appeared on the registry
Oct 6, 2026
Show all 2 updates
  1. Oct 16, 2026
    Not yet recruiting→Recruiting
    Konya Beyhekim Training and Research Hospital is now Recruiting
    + 2 other changes: verification date and date precision
  2. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07860645
Lead sponsor
Konya Beyhekim Training and Research Hospital
Responsible party
İbrahim Solak (Associate Professor, MD, Konya Beyhekim Training and Research Hospital) — Principal investigator
First posted
Oct 6, 2026
Start date
Oct 15, 2026
Primary completion
May 15, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

ARİFE KOÇAK, MD
Contact
arifekoccak@gmail.com
+905050696295
İBRAHİM SOLAK, MD
Contact
isolaktr@yahoo.com
+90533-659-11-71
İBRAHİM SOLAK, MD,AssocProf
principal investigator · Konya Beyhekim Training and Research Hospital
MUSTAFA YASİN ÖZTOPRAK, MD
study director · Konya Beyhekim Training and Research Hospital
ARİFE KOÇAK, MD
study director · Konya Beyhekim Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion